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of developing invasive breast cancer after
lobular carcinoma in situ
Vanessa Dania1†, Ying Liu1,2†, Foluso Ademuyiwa2,3, Jason D. Weber2,4 and Graham A. Colditz1,2*

Abstract
Background: Lobular carcinoma in situ (LCIS) of the breast is a risk factor of developing invasive breast cancer. We
evaluated the racial differences in the risks of subsequent invasive breast cancer following LCIS.
Methods: We utilized data from the Surveillance, Epidemiology, and End Results registries to identify 18,835
women diagnosed with LCIS from 1990 to 2015. Cox proportional hazards regression was used to estimate race/
ethnicity-associated hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) of subsequent invasive
breast cancer.
Results: During a median follow-up of 90 months, 1567 patients developed invasive breast cancer. The 10-year
incidence was 7.9% for Asians, 8.2% for Hispanics, 9.3% for whites, and 11.2% for blacks (P = 0.046). Compared to
white women, black women had significantly elevated risks of subsequent invasive breast cancer (HR 1.33; 95% CI
1.11, 1.59), and invasive cancer in the ipsilateral breast (HR 1.37; 95% CI 1.08, 1.72) and in the contralateral breast (HR
1.33; 95% CI 1.00, 1.76). Black women had significantly higher risks of invasive subtypes negative for both estrogen
receptor and progesterone receptor (HR 1.86; 95% CI 1.14, 3.03) and invasive subtypes positive for one or both of
receptors (HR 1.30; 95% CI 1.07, 1.59). The risk of subsequent invasive breast cancer was comparable in Asian
women and Hispanic women compared with white women.
Conclusions: Black women had a significantly higher risk of developing invasive breast cancer, including both
hormone receptor-positive and hormone receptor-negative subtypes, after LCIS compared with white counterparts.
It provides an opportunity to address health disparities.
Keywords: Breast cancer, Lobular carcinoma in situ, SEER, Race, Second primary cancer

Background
Lobular carcinoma in situ (LCIS) is a pre-malignant
breast lesion that increases a woman’s long-term risk of
developing invasive carcinoma [1–5]. Compared to the
general population, women diagnosed with LCIS have a
3-fold to 10-fold higher risk of invasive breast carcinoma
[1–7]. The annual incidence of subsequent breast cancer
in women diagnosed with LCIS is 1 to 2% per year [6,
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8]. LCIS is largely diagnosed in women between the ages
of 45 to 50 years old [8, 9]. LCIS does not commonly
present with palpable breast masses or calcification on
mammography; only 0.5 to 3.8% of benign breast biopsies are diagnosed with LCIS [7]. Prior analysis of National Cancer Institute’s Surveillance, Epidemiology, and
End Results (SEER) data has shown that the ageadjusted incidence of LCIS increased from 2.0 per 100,
000 in 2000 to 2.75 per 100,000 in 2009 [10]. This may
be due to increased surveillance and utilization of
mammography.
Although considered as low-risk pre-invasive or benign lesions, controversy persists regarding whether to
classify LCIS as a precursor of subsequent invasive carcinoma or just as a lesion that increases the risk of
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breast cancer in a woman’s lifetime [1, 9, 11]. This abnormal proliferation of cells frequently originates in the
terminal ductal lobular unit of the breast and may
spread to the ducts [12]. LCIS may also be associated
with the development of invasive ductal carcinoma, typically estrogen receptor-positive (ER+) lesions [13].
Pathological models of breast cancer progression have
proposed distinct ductal and lobular pathways from normal breast tissue to invasive breast cancer [14]. Ductal
carcinoma in situ (DCIS) and LCIS are pre-invasive
breast lesions among the two proposed pathways to invasive breast cancer. We and other groups have previously shown that among African American women,
DCIS is associated with excess risk of subsequent invasive breast cancer when compared to white women [15–
20]. Potential racial differences in the risk of subsequent
invasive breast cancer following LCIS are far less understood. In this study, we examined the associations between race/ethnicity and the risks of subsequent invasive
breast cancer in a population-based racially diverse
group of women with LCIS. Understanding of racial differences in LCIS outcomes will contribute to the development of patient management strategies and refine our
understanding of disparities in breast cancer incidence/
risk.

Methods
Patient selection

The cases included in this study were from the SEER
database. The data were derived from 17 SEER registries
which represent approximately 28% of the US population. De-identified SEER data were utilized thus exempting the study from review by our Institutional Review
Board. The analysis included women diagnosed with primary unilateral LCIS (no concurrent DCIS) between
January 1990 and June 2015 who had no prior cancer
history, were aged 20 or older, and were followed for at
least 6 months (n = 20,021). Patients who underwent bilateral mastectomy were excluded (n = 716). Race/ethnicity was determined as mutually exclusive categories of
non-Hispanic white (hereafter acknowledged as white),
non-Hispanic black (black), non-Hispanic Asian (Asian),
and Hispanic. The analysis excluded Pacific Islanders
and other racial classifications (n = 470). Thus, 18,835
women with LCIS were included in the analysis.
Outcomes

The primary outcome of interest is subsequent invasive
breast cancer, defined as invasive breast cancer, regardless of histological features, in either of the breasts or
metastatic breast cancer that was diagnosed at least 6
months after the initial LCIS to ensure that it was not
part of the index LCIS [15]. Subsequent invasive breast
cancers were classified to ipsilateral and contralateral
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invasive breast cancers. Subsequent invasive breast cancer was also subdivided by both ER and progesterone receptor (PR) status to examine the association between
race/ethnicity and risk of invasive subtypes defined by
both ER and PR.

Statistical analysis

To compare categorical and continuous variables across
racial/ethnic groups, we used the χ2 test and analysis of
variance, respectively. Person-years were calculated from
6 months after the initial LCIS diagnosis until the diagnosis date of the second primary breast tumor (invasive
or carcinoma in situ), death, or December 2015. The
Kaplan-Meier estimates of 10-year probabilities of subsequent invasive breast cancer were computed for each of
the four race/ethnic groups, and log-rank tests were performed to test for significant differences. We utilized the
Lunn-McNeil competing risk models, an extension of
the Cox proportional hazards regression models [21], to
estimate the race-associated hazard ratio (HR) and 95%
confidence interval (CI) of subsequent invasive breast
cancer. Subsequent carcinoma in situ was modeled as
separate competing outcomes. Specifically, each patient
had a separate observation for each type of outcomes
and the analysis was stratified on outcome types. Scaled
Schoenfeld residuals were used to confirm the assumptions of proportionality in Cox models. The risks of ipsilateral and contralateral invasive breast cancer were
analyzed using two separate competing risk models. We
also analyzed subsequent invasive breast cancer subtypes
defined by both ER and PR in black and white women
using the aforementioned competing risk models; tumors positive for ER and/or PR were classified as hormone receptor-positive (ER+/PR+), and tumors negative
for both ER and PR were classified as hormone receptornegative (ER−PR−). Likelihood ratio tests for heterogeneity were used to determine statistically significant differences in the associations of race/ethnicity with cancer
subtypes.
Each statistical model was adjusted for age (20–39,
40–49, 50–59, 60–69, or ≥ 70 years), year of LCIS diagnosis (1990–1999, 2000–2009, or 2010–2015), treatment
of LCIS (no surgical treatment, breast-conserving surgery alone, breast-conserving surgery followed by radiation therapy, unilateral mastectomy, bilateral
mastectomy, or unknown), and registries. The analyses
were stratified by age at the diagnosis of LCIS (< 50 years
vs ≥ 50 years). The interaction between race/ethnicity
and age at the diagnosis of LCIS was assessed by including a cross-product term in multivariable-adjusted
models. The statistical significance of an interaction
term was evaluated by the likelihood ratio test. All statistical analyses were conducted with SAS (9.4 version). A
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two-sided P < 0.05 was used to indicate statistical
significance.

Results
Among 18,835 women with LCIS, 78.6% were white,
8.2% were black, 4.6% were Asian, and 8.6% were Hispanic. Mean age was 54.1 (a range of 20–95). They were
followed for 90 months on average. While 9.9% of patients did not receive surgery, 83.0% had breastconserving surgery alone, 1.4% were treated with breastconserving surgery and radiation therapy, and 4.2% had
a unilateral mastectomy.
Table 1 presents the characteristics of patients by
race/ethnicity. Overall, women from racial/ethnic minority backgrounds were significantly younger at their LCIS
diagnosis. Asian women were more likely than the other
racial groups to undergo breast-conserving surgery
alone, while white women were more likely than racial
minority women to receive mastectomies.
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Among 18,835 patients, 1567 (8.3%) subsequently developed invasive breast cancer in either breast (n = 1536)
or other body parts (stage IV, n = 31) during the 90month follow-up. Of these subsequent invasive tumors,
801 (51.1%) were ductal, 408 (26.0%) were lobular, and
242 (15.4%) had both lobular and other types of histology. We observed a significant racial/ethnic difference
(P = 0.046) in the cumulative incidence of subsequent invasive breast cancer (Fig. 1a). The 10-year cumulative
risk of subsequent invasive breast cancer was 7.9% in
Asian women, 8.2% in Hispanic women, 9.3% in white
women, and 11.2% in black women. The multivariableadjusted RR of subsequent breast cancer was 1.33 (95%
CI 1.11, 1.59) in black women compared to white
women (Table 2). Asian and Hispanic women had a
similar risk compared to white women. We also examined the race-associated risk in patients diagnosed and
followed during three time intervals: between 1990 and
1999, between 2000 and 2009, and between 2010 and
2015 (Additional file 1: Table S1). The increased risk in

Table 1 Characteristics of women with lobular carcinoma in situ (LCIS) in the SEER by race and ethnicity, 1990 to 2015 (n = 18,835)
White

Black

Asian

Hispanic

14,811

1536

865

1623

54.7 (10.6)

53.3 (10.7)

51.0 (9.7)

51.5 (9.6)

20–39

3.3

5.7

6.2

5.3

40–49

32.9

34.8

45.4

44.4

50–59

35.3

34.1

31.7

31.0

60–69

17.7

16.8

11.2

13.7

≥ 70

10.8

8.6

5.4

5.6

Median (range), months

95 (6–311)

80 (6–309)

74 (6–310)

77 (6–311)

6–11 months

4.2

5.5

6.1

6.2

Number of cases
Age at diagnosis, %
Mean (SD)

Length of follow-up, %

12–59 months

27.3

32.7

35.1

33.8

60–119 months

30.2

30.4

30.5

30.6

≥ 120 months

38.3

31.5

28.2

29.4

1990–1999

19.2

16.3

12.5

13.8

2000–2009

53.2

47.5

46.8

48.1

2010–2015

27.7

36.3

40.7

38.1

No surgery

10.0

11.4

8.3

8.9

BCS alone

82.7

82.4

86.0

84.7

BCS and radiation

1.4

1.2

1.9

2.0

Mastectomy

4.5

3.5

2.8

3.2

Unknown

1.4

1.6

1.0

1.1

Year of the first LCIS diagnosis, %

Treatment

Abbreviations: SD standard deviation, BCS breast-conserving surgery, ER estrogen receptor, PR progesterone receptor
Race and ethnicity were classified into mutually exclusive categories of non-Hispanic white (hereafter referred to as white), non-Hispanic black (black), nonHispanic Asian (Asian), and Hispanic (Hispanic)
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Fig. 1 Cumulative incidences of subsequent invasive breast cancer in either breast or other body parts (a), ipsilateral invasive breast cancer (b),
and contralateral invasive breast cancer (c) among four racial/ethnic groups of women with LCIS

black women was consistently observed over time.
The analysis of race-associated risk of subsequent invasive breast cancer was also stratified by age at the
diagnosis of LCIS; there was no significant variation
in the association pattern between women diagnosed
under 50 years and those diagnosed at the age of 50
years and older (Additional file 2: Table S2). Among
the 17,843 women with breast-conserving surgery or
no definitive surgery, 909 (5.1%) had ipsilateral invasive breast cancer during a median follow-up of 89
months (range 6-311 months). We observed no statistically significant difference in the cumulative incidence of ipsilateral invasive breast cancer by race/
ethnicity (P = 0.20; Fig. 1b). Multivariable-adjusted
analysis (Table 2) showed that black women had a
significantly higher risk of ipsilateral invasive breast
cancer when compared to white women (HR 1.37;
95% CI 1.08, 1.72). There was no significant

difference in the risk of ipsilateral invasive breast cancer between Hispanic, Asian, and white women.
Among the 18,642 patients who had known treatment
status, 635 (3.4%) patients were diagnosed with contralateral invasive breast cancer during a median follow-up
of 91 months (range 6–311 months). There was no significant difference in the cumulative incidence of contralateral invasive breast cancer by race/ethnicity (P = 0.12;
Fig. 1c). The multivariable-adjusted HR of contralateral
invasive breast cancer in black women compared with
white women was 1.33 (95% CI 1.00, 1.76), which was
similar to the risk of subsequent invasive breast cancer
and the risk of ipsilateral invasive breast cancer (Table 2).
There was no significant difference in the risks of
contralateral breast cancer in Asian women and Hispanic women compared with white women.
An analysis of hormone receptor status in subsequent
invasive breast cancer was performed in white women

Table 2 Risk of subsequent invasive breast cancer overall and by laterality associated with race and ethnicity in women with LCIS
Subsequent invasive breast cancera
d

Ipsilateral invasive breast cancerb
e

Contralateral invasive breast cancerc

Person-years

Cases

HR (95% CI)

Person-years

Cases

HR (95% CI)

Person-years

Cases

HRf (95% CI)

White

130,213

1264

1.00

120,334

722

1.00

128,949

521

1.00

Black

11,935

142

1.33 (1.11, 1.59)

11,283

85

1.37 (1.08, 1.72)

11,818

57

1.33 (1.00, 1.76)

Asian

6434

55

0.83 (0.62, 1.10)

6137

33

0.87 (0.61, 1.25)

6406

22

0.78 (0.49, 1.24)

Hispanic

12,229

106

0.89 (0.72, 1.09)

11,564

70

0.99 (0.77, 1.27)

12,142

36

0.76 (0.54, 1.08)

Abbreviations: HR hazard ratio, 95% CI 95% confidence interval
a
Subsequent invasive breast cancer included invasive breast cancer in either breast and metastatic breast cancer. The analysis included 19,545 women with LCIS
b
The analysis was restricted to 17,843 women who did not have surgical treatment or received breast-conserving surgery for primary LCIS
c
The analysis was restricted to 18,642 women who did not have surgical treatment or received breast-conserving surgery or unilateral mastectomy for
primary LCIS
d
HRs were adjusted for age (20–39, 40–49, 50–59, 60–69, or ≥ 70 years) and year of the initial LCIS diagnosis (1990–1999, 2000–2009, or 2010–2015), registry, and
treatment for primary LCIS (no surgical treatment, breast-conserving surgery alone, breast-conserving surgery followed by radiation therapy, mastectomy,
or unknown)
e
The covariates were the same as the above. Treatment was categorized as no surgical treatment, breast-conserving surgery alone, or breast-conserving surgery
followed by radiation therapy
f
The covariates were the same as the above. Treatment was categorized as no surgical treatment, breast-conserving surgery alone, breast-conserving surgery
followed by radiation therapy, or mastectomy
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and black women (n = 16,347) (Table 3). Black women
had significantly higher risks of ER−PR− invasive breast
cancer (HR 1.86; 95% CI 1.14, 3.03) and ER+/PR+ invasive breast cancer (HR 1.30, 95% CI 1.07, 1.59) following
LCIS compared to white women. There was no significant variation in the associations with these two subtypes (Heterogeneity = 0.15).

Discussion
By utilizing SEER data from a racially diverse group of
women with LCIS, we assessed the association between
race/ethnicity and risks of subsequent invasive breast
cancer among 19,545 patients. Compared with white
women, black women had a significantly higher risk of
developing invasive breast cancer during the follow-up.
The risk of invasive breast cancer was increased by 37%
in the ipsilateral breast and increased by 33% in the
contralateral breast among black women. In addition,
black women had significantly higher risks of developing
ER+/PR+ and ER−PR− invasive breast cancer following
LCIS. Asian and Hispanic women did not display a significant difference in the risk of acquiring subsequent invasive breast cancer when compared to white women.
We observed a 10-year incidence of subsequent invasive breast cancer that was 7.9% in Asian women, 8.2%
in Hispanic women, 9.3% in white women, and 11.2% in
black women. Other investigators have reported a similar cumulative long-term incidence of second breast tumors after LCIS, but ignored associations with race. A
long-term follow-up study of 236 patients found that the
probability of developing subsequent invasive carcinoma
by 10 years after a diagnosis of LCIS was 13% [6].
Among 4853 women with LCIS identified from the
1973–1998 SEER database, there was a 7.1% minimum
risk of developing subsequent invasive breast tumors on
either the ipsilateral or contralateral breast [22]. Our
findings of a higher 10-year incidence of subsequent invasive breast cancer among black women compared to
other races support further investigation of the biological
Table 3 Risk of subsequent hormone receptor-defined invasive
breast cancer in black women with LCIS compared with white
counterparts (n = 16,347)
Personyears

ER+/PR+
Cases

HRa (95% CI)

ER− and PR−

White

130,213

1056

1.00

Black

11,935

115

1.30 (1.07, 1.59)

Cases
129
20

HRa (95% CI)
1.00
1.86 (1.14, 3.03)

Heterogeneity = 0.15
Abbreviations: HR hazard ratio, 95% CI 95% confidence interval, ER estrogen
receptor, PR progesterone receptor
a
HRs were adjusted for age (20–39, 40–49, 50–59, 60–69, or ≥ 70 years) and
year of the primary LCIS diagnosis (1990–1999, 2000–2009, or 2010–2015),
registry, and treatment for primary LCIS (no surgical treatment, breastconserving surgery alone, breast-conserving surgery followed by radiation
therapy, mastectomy, or unknown)

and non-biological factors that influence LCIS malignancy potential.
We assessed receptor expression in subsequent invasive
breast cancer following LCIS between black women and
white women, identifying that black women had a significantly higher risk for ER−PR− invasive subtypes. This correlated with other studies that have identified higher risks
of these receptor statuses in black women [23]. The observation of higher risk of ER−/PR− invasive tumors following LCIS among black women is noteworthy due to the
aggressiveness of those lesions. In a nationally representative population of DCIS patients diagnosed between 1990
and 2015, we demonstrated that compared with white
women, the risk of developing ER−PR− invasive breast
cancer was significantly increased by 86% (HR = 1.86, 95%
CI 1.57–2.20) in black women and by 40% in Asian
women (HR = 1.40, 95% CI 1.14–1.71). The associations
for ER−/PR− invasive cancer were stronger than the associations for ER+/PR+ subtypes (HR = 1.31, 95% CI 1.21–
1.43 in blacks; HR = 1.01, 95% CI 0.92–1.11 in Asians; Heterogeneity = 0.0004) [24]. Thus, the magnitude of the associations between black race and risk of invasive breast
cancer subtypes following LCIS and DCIS was similar.
Among women with benign breast disease, African
American identity was a significant risk factor for triple
negative breast cancer [25]. These findings warrant further
investigation of race-related biomarker profiling of premalignant breast lesions.
Within this study, differing treatment options were
noted to be favored among patients of various races.
Breast-conserving surgery alone was chosen by 83.0% of
patients, 9.9% did not receive surgery, 4.2% had a unilateral mastectomy, and 1.4% were treated with both
breast-conserving surgery and radiation therapy. Among
the patients who chose mastectomies, white women
were more likely to do so than women of racial minorities, and among the patients who chose no surgical interventions, black women were more likely to do so than
women in the other racial groups. These racial variations
in choices may be due to healthcare disparities, due to
greater preferences of a certain type of treatment based
on concomitant cultural norms, or due to the absence of
a standardized treatment for LCIS based on the uncertainty regarding the lesion’s malignancy potential [26,
27]. The National Comprehensive Cancer Network
(NCCN) guidelines (2018) states that surgical treatment
is not required for classic LCIS but acknowledges clinician’s choice to perform surgical excision with negative
margins for pleomorphic LCIS [26]. Considered as a
more aggressive subtype, pleomorphic LCIS contains
high-grade cytological features and usually is diagnosed
by calcifications on mammography [28].
Overall, NCCN guidelines recommend counseling patients on lifestyle modifications and follow-up
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surveillance appointments that include annual mammography, physical examinations, and interval history
every 6 to 12 months [26]. As a strategy of risk reduction, LCIS patients with higher risk, such as women with
BRCA 1 or BRCA 2 genetic mutations, may undergo bilateral prophylactic mastectomy [10]. There is limited
support for the addition of radiation therapy, but a small
cohort study suggested some benefits [13]. Based on the
more recent findings of Taylor et al. [29], there was no
significant difference in overall survival between patients
who received lumpectomy alone or lumpectomy with radiation treatment. Thus, considering the healthcare costs
and potential health risk of radiation treatments, lumpectomy alone could be a more appropriate standardized
treatment.
Adjuvant therapy such as chemoprevention is an effective method to reduce patient’s risk of developing
breast cancer, specifically ER+ invasive breast cancer [30,
31]. The NSABP P-1 trial reported that tamoxifen reduced the incidence of invasive breast lesions from 42.5
per 1000 women in the placebo group to 24.8 per 1000
women in the treatment group [30]. The NCCN guidelines support the administration of tamoxifen, raloxifene,
and aromatase inhibitors for 5 years as a risk reduction
strategy in LCIS patients [26]. Chemoprevention has
been associated with improved quality-adjusted life expectancy in premenopausal women when compared to
postmenopausal women [32].
This study has limitations. SEER registries did not provide information regarding endocrine therapy utilization,
family cancer history, comorbidities, obesity, alcohol
consumption, breast cancer screening after LCIS, and
socioeconomic status, which may influence the risk of
second breast tumors. Although an adequate analysis
was conducted from the LCIS patient data, receptor status in LCIS lesions, tumor grade, and tumor size information were unavailable for more than half of patients
and thus were not accounted for in the analysis. Treatment status was missing in less than 2% of patients.
Missing indicators were documented for this analysis.
This approach has been demonstrated to have no significant impacts on the estimated associations between exposures and cancer outcomes when missing is less than
50% [33].

a higher risk of developing these lesions when compared
to white women. Further research may refine posttreatment surveillance strategies and might better understand racial preferences for and provider-patient communications about LCIS treatment. In addition, studies
to identify which gene expression and molecular alterations in LCIS are associated with the risk of developing
invasive carcinoma may open new pathways for chemoprevention and improve patient care to reduce the disproportionate burden of breast cancer in black women.
These results also highlight the importance of understanding genetic background, early-life environmental/
behavioral exposures, and their interactions as contributors to racial differences in risk of developing invasive
breast cancer following LCIS.

Conclusions
Our study provides the largest population-based analysis
on the association between race/ethnicity and the development of subsequent invasive breast cancer after LCIS
and for the first time addresses the risk of hormone
receptor-negative breast cancer following LCIS. Black
women with LCIS had an elevated risk of subsequent invasive breast cancer, including both ER+/PR+ and ER
−PR− tumors. Asian and Hispanic women did not have
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